Litcius/Paper detail

The discovery of a new antibody for BRIL-fused GPCR structure determination

Hikaru Miyagi, Hidetsugu Asada, Michihiko Suzuki, Yuichi Takahashi, Mai Yasunaga, Chiyo Suno, So Iwata, Junichi Saito

2020Scientific Reports33 citationsDOIOpen Access PDF

Abstract

Abstract G-protein-coupled receptors (GPCRs)—the largest family of cell-surface membrane proteins—mediate the intracellular signal transduction of many external ligands. Thus, GPCRs have become important drug targets. X-ray crystal structures of GPCRs are very useful for structure-based drug design (SBDD). Herein, we produced a new antibody (SRP2070) targeting the thermostabilised apocytochrome b562 from Escherichia coli M7W/H102I/R106L (BRIL). We found that a fragment of this antibody (SRP2070Fab) facilitated the crystallisation of the BRIL-tagged, ligand bound GPCRs, 5HT 1B and AT 2 R. Furthermore, the electron densities of the ligands were resolved, suggesting that SPR2070Fab is versatile and adaptable for GPCR SBDD. We anticipate that this new tool will significantly accelerate structure determination of other GPCRs and the design of small molecular drugs targeting them.

Topics & Concepts

G protein-coupled receptorComputational biologyReceptorIntracellularDrug discoveryLigand (biochemistry)ChemistrySignal transductionAntibodyCell biologyBiologyBiochemistryGeneticsReceptor Mechanisms and SignalingMonoclonal and Polyclonal Antibodies ResearchNeuropeptides and Animal Physiology
The discovery of a new antibody for BRIL-fused GPCR structure determination | Litcius